Genzyme,
a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced that
Genzyme’s Head of Rare Diseases, Rogerio Vivaldi, MD, has been honored
as the Genetic Disease Foundation’s Industry Person of the Year. The
award is given to an individual in the life sciences industry who has
made outstanding contributions to advancing medical research and
bringing new therapies to people living with rare genetic diseases.
“For more than 20 years, Dr. Vivaldi has worked to identify the unmet
needs of those living with rare genetic diseases, such as Gaucher
disease,” said Elisa Ross, President of the Genetic Disease Foundation
(GDF). “We are pleased to recognize Dr. Vivaldi for his dedication and
commitment to improving patients’ lives.”
The award will be presented tonight at the GDF Gala at New York’s Gotham
Hall. The event will raise funds for the Department of Genetics and
Genomic Sciences, Icahn School of Medicine at Mount Sinai.
“I am truly honored by this award. As a physician in Brazil, I saw
firsthand the importance of diagnosis and treatment for rare genetic
diseases,” said Dr. Vivaldi. “At Genzyme we continue the mission to
develop and deliver transformative therapies to all patients affected by
rare genetic diseases.”
The Genetic Disease Foundation is a non-profit organization established
in 1997 by patients and families affected by genetic disorders. The
Foundation’s mission is to help prevent and treat genetic diseases by
supporting research and counseling and conducting educational
initiatives.
About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative
therapies for patients affected by rare and debilitating diseases for
over 30 years. We accomplish our goals through world-class research and
with the compassion and commitment of our employees. With a focus on
rare diseases and multiple sclerosis, we are dedicated to making a
positive impact on the lives of the patients and families we serve. That
goal guides and inspires us every day. Genzyme’s portfolio of
transformative therapies, which are marketed in countries around the
world, represents groundbreaking and life-saving advances in medicine.
As a Sanofi company, Genzyme benefits from the reach and resources of
one of the world’s largest pharmaceutical companies, with a shared
commitment to improving the lives of patients. Learn more at www.genzyme.com.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops
and distributes therapeutic solutions focused on patients’ needs. Sanofi
has core strengths in the field of healthcare with seven growth
platforms: diabetes solutions, human vaccines, innovative drugs,
consumer healthcare, emerging markets, animal health and the new
Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York
(NYSE: SNY).
Genzyme® is a registered trademark. All
rights reserved.
